Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icatibant - Takeda

Next Previous
X
Search
Drug Profile

Icatibant - Takeda

Alternative Names: Firazyr; HOE-140; Icatibant; Icatibant acetate; JE-049; SHP-667; TAK-667

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Jerini; sanofi-aventis; Shire; Takeda
  • Class Analgesics; Antiallergics; Antiarrhythmics; Antifibrotics; Cardiovascular therapies; Kinins; Neuropeptides; Oligopeptides; Vascular disorder therapies
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Capillary leak syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Preregistration Submission Withdrawal Angioedema
  • No development reported Capillary leak syndrome; Liver cirrhosis
  • Discontinued Arrhythmias; Musculoskeletal pain; Myocardial infarction; Pancreatitis; Rhinitis

Most Recent Events

  • 27 Jul 2021 Takeda completes a phase III trial in Hereditary angioedema (In adolescents, In children) in Japan (SC) (NCT04654351)
  • 15 Jan 2021 Phase-III clinical trials in Hereditary angioedema (In adolescents, In children) in Japan (SC) (NCT04654351)
  • 04 Dec 2020 Takeda plans a phase III trial for Hereditary angioedema (In children, In adolescent) in Japan (SC) in January 2021 (NCT04654351)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top